Betagenon AB is a pharmaceutical company based in Umeå that specializes in the activation of AMP-activated protein kinase (AMPK) for the treatment of metabolic diseases. The company is conducting research on ATX-304, an AMPK activator, and has reported studies indicating its potential to reduce oxidative stress. Their work also includes investigations into the improvement of metabolic-associated steatotic liver disease (MASLD) through metabolic switching, showcasing a commitment to advancing solutions for metabolic health.
The company is actively engaged in preclinical research and plans to present data at the ENDO 2025 conference, highlighting their findings on ATX-304's effects on kidney injury and the implications of age-related decreases in AMPK signaling. Betagenon AB collaborates with the scientific community to disseminate research findings, contributing to the broader understanding of metabolic health and the potential therapeutic applications of AMPK activation. Their featured publications underscore significant advancements in this area of study.